Endeavor BioMedicines

Acquisition, funding and merger involving Endeavor BioMedicines.

• Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).

View the org chart displaying its 15 main executives

Most searched biographies at Endeavor BioMedicines

• John Hood, Chief Executive Officer and Director
• Andrew Lam, Director
• Noelle Hutchins, Director

Popular executive movements at Endeavor BioMedicines

• Chris Krueger has joined the company as Chief Operating Officer  (posted on April 17 2024).
• Vishaal Turakhia has joined the company as Chief Financial Officer  (posted on March 15 2024).
• Enoch Kariuki, who was Director, is promoted to President  (posted on March 15 2024).

Click here to view some more movements at Endeavor BioMedicines

Create your alert
to follow the executive moves at Endeavor BioMedicines.

Endeavor BioMedicines has 2,288 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Attovia Therapeutics has just announced a $150 Million fundraising (posted on May 14 2024).
• Bruker has announced the acquisition of NanoString Technologies  (posted on May 13 2024).
• Aardvark Therapeutics has just announced a $85 Million fundraising (posted on May 12 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Carl Gordon - Director at Adicet Bio
• Vik Bajaj - Director at Interline Therapeutics

Learn more about the Biotechnology industry >

Press releases by Endeavor BioMedicines

• Media Coverage | Endeavor BioMedicines
• Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial Officer | Endeavor Biomedicines
• Endeavor BioMedicines Successfully Completes Phase 2a Trial of ENV-101 in Patients with Idiopathic Pulmonary Fibrosis | Endeavor Biomedicines
• Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. to Board of Directors | Endeavor Biomedicines
• Endeavor BioMedicines Appoints Paul Frohna, M.D., Ph.D., as Chief Medical Officer | Endeavor Biomedicines
• Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC) | Endeavor Biomedicines
• Endeavor Launches With $62m And A Hedgehog Inhibitor From Lilly
• Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline | Endeavor Biomedicines
• Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101 (Taladegib) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) | Endeavor Biomedicines
• Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib) | Endeavor Biomedicines
• View more press releases Close

Social media about Endeavor BioMedicines

• Endeavor BioMedicines on Wikipedia, Google News & Yahoo Finance
• Endeavor BioMedicines on LinkedIn, Twitter & YouTube

Contact by email its executives including Bernard Davitian

Call Endeavor BioMedicines at +1 858...

View the org chart

Register to receive your alert

Report an error